Hi Mithrams,
All very good questions and comments.
The quick shift in strategy proliferated by the loss of our NMDC/NLCIL partnership, meant we had to make some hard decisions about what to progress and what not to. The purchase of the CDP-WTE technology was undertaken at the time we understood that the Indian deal would proceed so was pursued to support the next steps expected in the Latrobe Valley. All of the potential and all of the attributes available to us in utilising this technology is still valid. The difference is that it is now subordinate to the efforts in upgrading our Bacchus Marsh plant in pursuit of operational earnings. We are maintaining the patents and IP protection on this technology but our efforts to commercialise will be driven by a) availability of resources after allocation to our stated priorities and b) clear and unequivocal market evidence of a demand for the progressive application of this tech (read that as a partner approaching us to JV or something of that ilk)
- Forums
- ASX - By Stock
- ECT
- ECT - Q&A Session - India Update
ECT - Q&A Session - India Update, page-33
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ECT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.343M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 4003629 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 15249389 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 4003629 | 0.002 |
27 | 35956532 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 15249389 | 23 |
0.004 | 7303519 | 10 |
0.005 | 3296859 | 21 |
0.006 | 3178567 | 7 |
0.007 | 918333 | 2 |
Last trade - 16.12pm 13/11/2024 (20 minute delay) ? |
Featured News
ECT (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online